Welcome to the UPF Digital Repository

Building the future therapies for Down syndrome: the third international conference of the T21 research society

Show simple item record

dc.contributor.author Dierssen, Mara
dc.contributor.author Martínez de Lagrán Cabredo, María
dc.contributor.author Vazquez, Anna
dc.contributor.author Bhattacharyya, Anita
dc.date.accessioned 2023-10-05T06:06:43Z
dc.date.available 2023-10-05T06:06:43Z
dc.date.issued 2021
dc.identifier.citation Dierssen M, Herault Y, Helguera P, Martínez de Lagran M, Vazquez A, Christian B et al. Building the future therapies for Down syndrome: the third international conference of the T21 research society. Mol Syndromol. 2021;12(4):202-18. DOI: 10.1159/000514437
dc.identifier.issn 1661-8769
dc.identifier.uri http://hdl.handle.net/10230/58045
dc.description.abstract Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Karger (S. Karger AG)
dc.relation.ispartof Mol Syndromol. 2021;12(4):202-18
dc.rights © 2021 S. Karger AG, Basel http://dx.doi.org/10.1159/000514437 ‘This is the peer-reviewed but unedited manuscript version of the following article: Mol Syndromol. 2021;12(4):202-18. DOI: 10.1159/000514437. The final, published version is available at http://www.karger.com/?doi=10.1159/000514437.’
dc.title Building the future therapies for Down syndrome: the third international conference of the T21 research society
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1159/000514437
dc.subject.keyword Alzheimer's disease
dc.subject.keyword Biomarkers
dc.subject.keyword Down syndrome
dc.subject.keyword Intellectual disability
dc.subject.keyword Language impairment
dc.subject.keyword Mouse models
dc.subject.keyword Neurodevelopmental disorders
dc.subject.keyword Trisomy 21 Research Society
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking